Urothelial carcinoma
Conditions
Interventions
None listed
Sponsors
Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients 1.Patients aged over 20 years 2.Patients with urothelial carcinoma living in Japan who have underwent cystectomy or nephroureterectomy 3. Patients more than 3 months after cystectomy or nephroureterectomy Physicians Physicians who have medical license in Japan and have performed cystectomy or nephroureterectomy within 5 years
Exclusion criteria
Exclusion criteria: Patients or their family members who are engaged in a pharmaceutical, medical, or survey-related job
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of respondents with anxiety and worry in patients underwent urothelial carcinoma surgery and the changes over time from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of respondents with recognition about patient's anxiety and worry in patients underwent urothelial cancer surgery and the changes over times from baseline/ Willingness for adjuvant therapy in patients underwent urothelial carcinoma surgery/ The extent to which patients are conveying their anxiety to their physicians/ Actual treatment status and goals of physicians with experience of surgery for urothelial cancer | — |
Countries
Japan
Contacts
Public ContactShinsuke Hamamatsu
3H Clinical Trial Co., Ltd. Insight & Outcome Group
Outcome results
None listed